ArticleEndocrine2026
Efficacy and safety of GLP-1 receptor agonists in the treatment of type 2 diabetes and/or obesity in patients with Cushing’s syndrome: a multicenter retrospective study.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCushing’s syndrome (CS) is characterized by profound metabolic derangements, including obesity, insulin resistance, diabetes mellitus, and dyslipidemia. Glucagon-like peptide-1 receptor agonists (GLP-1RA) have shown potent metabolic benefits in type 2 diabetes (T2D) and obesity, but their efficacy and safety in CS remain unexplored.
objectiveTo assess the metabolic efficacy and safety of GLP-1RAs in patients with CS and concurrent T2D and/or obesity.
methodsThis retrospective multicenter study included 20 adults with biochemically confirmed CS treated with GLP-1RAs (liraglutide, semaglutide, tirzepatide, or dulaglutide) for ≥ 3 months. Anthropometric, hemodynamic, metabolic, hepatic, and hormonal parameters were compared before and after therapy using paired statistical tests.
resultsAfter a median follow-up of 13 months, significant reductions were observed in body weight (− 10.3 ± 8.8 kg; p < 0.001) and BMI (− 4.2 ± 2.8 kg/m²; p < 0.001). Fasting glucose (− 12.1 ± 35.3 mg/dL; p = 0.015) and HbA1c (− 0.5 ± 0.9%; p = 0.011) decreased significantly. No significant changes occurred in blood pressure or lipid parameters. Liver enzymes improved, with decreases in ALT (− 3.9 ± 21.4 U/L; p = 0.005) and GGT (− 25.9 ± 57.3 U/L; p = 0.012), while the slight reduction in AST (− 5.2 ± 9.2 U/L; p = 0.046) was statistically significant but not clinically relevant. Hormonal parameters, including ACTH and cortisol levels, remained stable. GLP-1RAs were generally well tolerated, with only mild gastrointestinal side effects in 26.3% of patients.
conclusionsGLP-1RA therapy in patients with CS and associated metabolic disorders led to significant improvements in weight, BMI, and glycemic control without worsening cortisol dynamics or liver function. Although limited by its retrospective design and small sample size, this study supports the safety and potential metabolic efficacy of GLP-1RAs in patients with CS, suggesting that these agents may constitute a useful adjunct for managing obesity and diabetes in this population.
Indexed as
Identifiers
41803337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.